QuantHealth Marks a Landmark Quarter as Simulation-First Clinical Development Gains Momentum

New capital, rapid product adoption, and expanded capabilities drove the company’s commercial and scientific growth

TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth, a leader in AI-driven clinical trial simulation, today announced a quarter of milestones that demonstrate its impact in accelerating biopharma’s adoption of simulation-first clinical development. Headlined by its Series B, the quarter also brought rapid adoption of QuantHealth’s predictive competitive positioning solution, expanded therapeutic coverage, and a growing roster of clients and partners.

Together, these developments reflect QuantHealth’s expanding role in helping life sciences organizations design and optimize clinical trials and bring safer, more effective therapies to patients faster. Highlights from the quarter include:

• Scaling with New Capital: QuantHealth closed a $45 million Series B, which will fund continued expansion of the company’s R&D capabilities, product portfolio, and go-to-market capabilities, extending its impact across a larger share of the drug development process.
• Expanding Market Adoption: Since its recent launch, QuantHealth’s predictive competitive positioning capabilities have been adopted by three leading life sciences organizations. This first-in-class offering predicts an asset’s clinical and commercial outcomes relative to its competition while still in development. The quick adoption reflects strong demand for a shared, forward-looking view of market positioning years before an asset’s launch.
• Growing Global Reach: QuantHealth grew its global footprint this quarter through new collaborations in APAC with GC Cell (Korea), a leader in the cell and gene therapy sector, and NovelWise (Taiwan), a clinical-stage biotechnology company developing novel oncology therapeutics, extending simulation-first clinical development into new markets.
• Increasing Therapeutic Coverage: The company expanded into new indications in Q3, including rare disease and neurological conditions, broadening the range of pharmaceutical and biotechnology programs that can benefit from simulation-first clinical development.
• Deepening Technology Partnerships: QuantHealth continued to deepen its technology partnerships this quarter, joining Databricks as a “built-on partner” helping scale its simulation infrastructure and making it easier for clients to integrate QuantHealth’s capabilities into their existing workflows and technology stacks.

“Life sciences can’t wait for innovation, and this quarter’s successes show what happens when you build for where the market is headed. The industry has clearly embraced simulation-first clinical development for their individual assets and protocols, and it’s an exciting time for QuantHealth,” said Orr Inbar, CEO and Co-founder of QuantHealth. “As we build what the industry needs next, we’re bringing a new approach to simulation that lets biopharma get answers to more of the questions that matter — faster, with greater precision, and within their existing workflows. Soon, the value of our simulations will compound, moving from the protocol to the entire portfolio.”

This quarter builds on a strong second quarter, when QuantHealth helped make simulation-first clinical development a leading topic across the industry. The company convened 100 biopharma, technology, and business leaders, including executives from Sanofi, AstraZeneca, Bristol Myers Squibb, Roche, Accenture, AWS, Databricks, and ZS, at its AI in Clinical Development Summit in New York City. QuantHealth’s Large Real-World Drug Model (LRDM) was also recognized by Newsweek’s AI Impact Awards, and the company was named to Qumra Capital’s “Tomorrow’s Growth Companies 2026” list.

To learn more, visit quanthealth.ai.

About QuantHealth

QuantHealth is an AI-driven clinical trial simulation company. Its portfolio includes more than 600 trial simulations across 30 diseases, with up to 90% prediction accuracy, and it draws on a large real-world dataset to help life sciences and biotechnology organizations improve the odds of clinical trial success. QuantHealth solutions use real-world data and predictive modeling to simulate trials at scale, optimize protocols, reduce risk, and accelerate timelines. The company is a trusted partner to 12 of the world’s top 20 pharmaceutical companies.